Brazil pharmaceutical supply chain vulnerabilities exposed by pandemic disruptions

Brazil pharmaceutical supply chain vulnerabilities came into sharp focus when heavy reliance on imported active pharmaceutical ingredients and finished medicines, together with limited domestic innovation, triggered acute supply disruptions between 2018 and 2022. Regulatory notifications recorded 11,657 discontinuations overall, roughly 38 percent of them during the COVID-19 emergency, while cardiovascular agents accounted for 22 percent of pandemic-era cases. Several cardiovascular products posted cumulative procurement price increases above 100 percent, with the steepest median rises occurring in 2020.

Four-Source Data Integration Tracks Market Shifts

A descriptive retrospective design merged four administrative databases to link discontinuation events with pricing dynamics. Primary records came from the Brazilian Health Surveillance Agency (ANVISA) Notification Panel, maximum allowable prices from the Drug Market Regulation Chamber (CMED) lists, and actual acquisition costs from the Health Price Database (BPS) for state and municipal purchases plus the Integrated General Services Administration System (SIASG) for federal transactions. Notifications were divided into pre-pandemic, pandemic, and post-pandemic periods; medicines were classified at the third level of the Anatomical Therapeutic Chemical system and cross-checked against the National List of Essential Medicines (RENAME).

Cardiovascular Agents Drive Discontinuation and Price Gaps

Commercial reasons explained more than 70 percent of all discontinuation notices, with temporary halts exceeding 75 percent, especially during the pandemic. Cardiovascular products topped anatomical-group rankings, and renin-angiotensin agents showed the sharpest proportional increase from 2020 onward. Median CMED maximum prices fell 29.4 percent between 2019 and 2020, while public-procurement medians rose 18.5 percent; the average gap between regulatory ceilings and observed BPS or SIASG prices exceeded 70 percent and reached 90 percent in some years. These patterns underscore Brazil pharmaceutical supply chain vulnerabilities in consistent access to essential medicines.

Ad

Targeted Reforms to Strengthen Domestic Capacity

The single consumer-price index used by CMED for annual adjustments has not kept pace with competitive realities for older, high-volume generics, widening the misalignment between ceilings and transaction prices. Updating price-regulation parameters to reflect competition intensity and time since market entry, while expanding local active-ingredient production, would directly mitigate Brazil pharmaceutical supply chain vulnerabilities and help secure reliable supplies of essential cardiovascular therapies.